

Secretary of State
Certificate and Order for Filing
PERMANENT ADMINISTRATIVE RULES

FILED
12-30-15 2:20 PM
ARCHIVES DIVISION
SECRETARY OF STATE

I certify that the attached copies are true, full and correct copies of the PERMANENT Rule(s) adopted on 12/14/2015 by the
Oregon Board of Naturopathic Medicine 850

Agency and Division Administrative Rules Chapter Number
Anne Walsh (971) 673-0193

Rules Coordinator Telephone
800 NE Oregon St., Suite 407, Portland, OR 97232

Address

To become effective Upon filing. Rulemaking Notice was published in the November 2015 Oregon Bulletin.

RULE CAPTION

Amend 850-060-0226 to include recommended changes by the Formulary Council

Not more than 15 words that reasonably identifies the subject matter of the agency's intended action.

RULEMAKING ACTION

Secure approval of new rule numbers with the Administrative Rules Unit prior to filing.

ADOPT:

AMEND:

850-060-0226

REPEAL:

RENUMBER:

AMEND AND RENUMBER:

Statutory Authority:

ORS 685.125 and 685.145

Other Authority:

Statutes Implemented:

685.145

RULE SUMMARY

- (8) Remove "Selective Serotonin Agonists";
- (19) Change "Hormone and Synthetic Substitutes" to "Endocrine Metabolic Agents";
Add "Corticosteroids" and "Prostaglandin"
- (21) Remove "except for Mifepristone" and add "not to be used as an abortifacient".
- (25) Add "and Nutrients";
- (26) Delete limiting language after Biologic Response Modifiers;
Add "Hyaluronic Acid" and "Oxygen";
and make some spelling corrections.

Anne Walsh

Rules Coordinator Name

Anne.Walsh@state.or.us

Email Address

850-060-0226

Formulary Compendium Classifications

The Formulary Council has approved the following pharmacologic-therapeutic classifications in addition to drugs previously approved by the Formulary Council and listed in 850-060-0225. This listing does not supersede the education and training requirement established in 850-060-0212 for administration of IV agents. The Formulary Council may consider new agents, substances and pharmacologic-therapeutic classifications for addition to this list.

- (1) Antihistamine Drugs;
 - (a) First Generation Antihistamine Drugs;
 - (A) Ethanolamine Derivatives;
 - (B) Ethylenediamine Derivatives;
 - (C) Phenothiazine Derivatives;
 - (D) Piperazine Derivatives;
 - (E) Propylamine Derivatives;
 - (F) Miscellaneous Derivatives;
 - (b) Second Generation Antihistamines.
- (2) Anti-Infective Agents;
 - (a) Anthelmintics;
 - (b) Antibacterials;
 - (A) Aminoglycosides;
 - (B) Cephalosporins;
 - (i) First Generation Cephalosporins;
 - (ii) Second Generation Cephalosporins;
 - (iii) Third Generation Cephalosporins;
 - (iv) Fourth Generation Cephalosporins.
 - (C) Miscellaneous β -Lactams;
 - (i) Carbacephems;
 - (ii) Carbapenems;
 - (iii) Cephamycins;
 - (iv) Monobactams.
 - (D) Chloramphenicol;
 - (E) Macrolides.
 - (i) Erythromycins;
 - (ii) Ketolides;
 - (iii) Other Macrolides.
 - (F) Penicillins;
 - (i) Natural Penicillins;
 - (ii) Aminopenicillins;
 - (iii) Penicillinase-resistant Penicillins;
 - (iv) Extended-spectrum Penicillins.
 - (G) Quinolones;
 - (H) Sulfonamides;
 - (I) Tetracyclines: Glycylcyclines;
 - (J) Antibacterials, Miscellaneous.
 - (i) Aminocyclitols;
 - (ii) Bacitracins;
 - (iii) Cyclic Lipopeptides;
 - (iv) Glycopeptides;
 - (v) Lincomycins;

- (vi) Oxazolidinones;
- (vii) Polymyxins;
- (viii) Rifamycins;
- (ix) Streptogramins;
- (c) Antifungals;
- (A) Allylamines;
- (B) Azoles;
- (C) Echinocandins;
- (D) Polyenes;
- (E) Pyrimidines;
- (F) Antifungals, Miscellaneous.
- (d) Antimycobacterials;
- (A) Antituberculosis Agents;
- (B) Antimycobacterials, Miscellaneous.
- (e) Antivirals;
- (A) Adamantanes;
- (B) Antiretrovirals;
- (i) HIV Fusion Inhibitors;
- (ii) HIV Protease Inhibitors;
- (iii) Integrase Inhibitors;
- (iv) Nonnucleoside Reverse Transcriptase Inhibitors;
- (v) Nucleoside and Nucleotide Reverse Transcriptase Inhibitors
- (C) Interferons;
- (D) Monoclonal Antibodies;
- (E) Neuraminidase Inhibitors;
- (F) Nucleosides and Nucleotides;
- (G) Antivirals, Miscellaneous;
- (f) Antiprotozoals;
- (A) Amebicides;
- (B) Antimalarials;
- (C) Antiprotozoals, Miscellaneous.
- (3) Antineoplastic Agents (oral and topical only) limited to the following:
 - (a) 5FU;
 - (b) Anastrozole;
 - (c) Letrozole;
 - (d) Mechlorethamine;
 - (e) Megestrol;
 - (f) Mercaptopurine;
 - (g) Methotrexate;
 - (h) Tamoxifen;
 - (i) Tretinoin.
- (4) Autonomic Drugs;
 - (a) Parasympathomimetic (Cholinergic) Agents;
 - (b) Anticholinergic Agents: Antimuscarinics/ Antispasmodics;
 - (c) Sympathomimetic (Adrenergic) Agents;
 - (A) α -Adrenergic Agonists;
 - (B) β - Adrenergic Agonists;
 - (i) Non-selective β - Adrenergic Agonists;
 - (ii) Selective β_1 - Adrenergic Agonists;
 - (iii) Selective β_2 - Adrenergic Agonists;
 - (C) α -And β -Adrenergic Agonists;
 - (d) Sympatholytic (Adrenergic Blocking) Agents;

- (e) Skeletal Muscle Relaxants;
 - (A) Centrally Acting Skeletal Muscle Relaxants;
 - (B) Direct-acting Skeletal Muscle Relaxants;
 - (C) GABA-derivative Skeletal Muscle Relaxants;
 - (D) Neuromuscular Blocking Agents;
 - (E) Skeletal Muscle Relaxants, Miscellaneous.
- (f) Autonomic Drugs, Miscellaneous.
- (5) Blood Derivatives.
 - (6) Blood Formation, Coagulation, and Thrombosis;
 - (a) Antianemia Drugs: Iron Preparations;
 - (b) Antithrombotic Agents;
 - (A) Anticoagulants;
 - (i) Coumarin Derivatives;
 - (ii) Direct Thrombin Inhibitors;
 - (iii) Heparins;
 - (iv) Anticoagulants, Miscellaneous.
 - (B) Platelet-reducing Agents;
 - (C) Platelet-aggregation Inhibitors;
 - (D) Thrombolytic Agents;
 - (c) Hematopoietic Agents;
 - (d) Hemorrhologic Agents;
 - (e) Antihemorrhagic Agents;
 - (A) Antiheparin Agents;
 - (B) Hemostatics.
 - (7) Cardiovascular Drugs;
 - (a) Cardiac Drugs;
 - (A) Antiarrhythmic Agents;
 - (i) Class Ia Antiarrhythmics;
 - (ii) Class Ib Antiarrhythmics;
 - (iii) Class Ic Antiarrhythmics;
 - (iv) Class III Antiarrhythmics;
 - (v) Class IV Antiarrhythmics.
 - (B) Cardiotonic Agents;
 - (C) Cardiac Drugs, Miscellaneous.
 - (b) Antilipemic Agents;
 - (A) Bile Acid Sequestrants;
 - (B) Cholesterol Absorption Inhibitors;
 - (C) Fibric Acid Derivatives;
 - (D) HMG-CoA Reductase Inhibitors;
 - (E) Antilipemic Agents, Miscellaneous.
 - (c) Hypotensive Agents;
 - (A) Calcium-Channel Blocking Agents;
 - (B) Central α -Agonists;
 - (C) Direct Vasodilators;
 - (D) Peripheral Adrenergic Inhibitors.
 - (d) Vasodilating Agents;
 - (A) Nitrates and Nitrites;
 - (B) Phosphodiesterase Inhibitors;
 - (C) Vasodilating Agents, Miscellaneous.
 - (e) Sclerosing Agents;
 - (f) α -Adrenergic Blocking Agents;
 - (g) β -Adrenergic Blocking Agents;

- (h) Calcium-Channel Blocking Agents;
 - (A) Dihydropyridines;
 - (B) Calcium-Channel Blocking Agents, Miscellaneous;
 - (i) Renin-Angiotensin-Aldosterone System Inhibitors;
 - (A) Angiotensin-Converting Enzyme Inhibitors;
 - (B) Angiotensin II Receptor Antagonists;
 - (C) Mineralocorticoid (Aldosterone) Receptor Antagonists;
 - (D) Renin Inhibitors.
 - (8) Central Nervous System Agents;
 - (a) Analgesics and Antipyretics;
 - (A) Nonsteroidal Anti-inflammatory Agents;
 - (i) Cyclooxygenase-2 (COX-2) Inhibitors;
 - (ii) Salicylates;
 - (iii) Other Nonsteroidal Anti-inflammatory Agents;
 - (B) Opiate Agonists;
 - (C) Opiate Partial Agonists;
 - (D) Analgesics and Antipyretics, Miscellaneous.
 - (b) Opiate Antagonists;
 - (c) Anticonvulsants;
 - (A) Benzodiazepines;
 - (B) Hydantoins;
 - (C) Succinimides;
 - (D) Anticonvulsants, Miscellaneous.
 - (d) Psychotherapeutic Agents;
 - (A) Antidepressants;
 - (i) Monoamine Oxidase Inhibitors;
 - (ii) Selective Serotonin- and Norepinephrine-reuptake Inhibitors;
 - (iii) Selective Serotonin- Reuptake Inhibitors;
 - (iv) Serotonin Modulators;
 - (v) Tricyclics and Other Norepinephrine-reuptake Inhibitors.
 - (vi) Antidepressants, Miscellaneous.
 - (B) Antipsychotics.
 - (e) Anorexigenic Agents and Respiratory and Cerebral Stimulants.
 - (A) Amphetamines.
 - (B) Anorexigenic Agents and Respiratory and Cerebral Stimulants, Miscellaneous.
 - (f) Anxiolytics, Sedatives, and Hypnotics, does not include Barbiturates;
 - (A) Benzodiazepines;
 - (B)(i) Anxiolytics, Sedatives, and Hypnotics; Miscellaneous;
 - (ii) Nitrous oxide;
 - (g) Antimanic Agents;
 - (h) Antimigraine Agents: ~~Selective Serotonin Agonists~~;
 - (i) Antiparkinsonian Agents;
 - (A) Adamantanes;
 - (B) Anticholinergic Agents;
 - (C) Catechol-O-Methyltransferase (COMT) Inhibitors;
 - (D) Dopamine Precursors;
 - (E) Dopamine Receptor Agonists;
 - (i) Ergot-derivative Dopamine Receptor Agonists;
 - (ii) Non-ergot-derivative Dopamine Receptor Agonists;
 - (F) Monoamine Oxidase B Inhibitors;
 - (j) Central Nervous System Agents, Miscellaneous.
- (9) Contraceptives (foams, devices).

- (10) Diagnostic Agents.
- (11) Disinfectants (for Agents used on objects other than skin).
- (12) Electrolytic, Caloric, and Water Balance;
 - (a) Acidifying Agents;
 - (b) Alkalinizing Agents;
 - (c) Ammonia Detoxicants;
 - (d) Replacements Preparations;
 - (e) Ion-Removing Agents;
 - (A) Calcium-removing Agents;
 - (B) Potassium-removing Agents;
 - (C) Phosphate-removing Agents;
 - (D) Other Ion-removing Agents;
 - (f) Caloric Agents;
 - (g) Diuretics;
 - (A) Loop Diuretics;
 - (B) Osmotic Diuretics;
 - (C) Potassium-sparing Diuretics;
 - (D) Thiazide Diuretics;
 - (E) Thiazide-like Diuretics;
 - (F) Diuretics, Miscellaneous;
 - (h) Irrigation Solutions;
 - (i) Uricosuric Agents.
- (13) Enzymes.
- (14) Respiratory Tract Agents;
 - (a) Antihistamines;
 - (b) Antitussives;
 - (c) Anti-inflammatory Agents;
 - (A) Leukotriene Modifiers;
 - (B) Mast-cell Stabilizers;
 - (d) Expectorants;
 - (e) Pulmonary Surfactants;
 - (f) Respiratory Agents, Miscellaneous.
- (15) Eye, Ear, Nose, and Throat (EENT) Preparations;
 - (a) Antiallergic Agents;
 - (b) Anti-infectives;
 - (A) Antibacterials;
 - (B) Antifungals;
 - (C) Antivirals;
 - (D) Anti-infectives, Miscellaneous.
 - (c) Anti-inflammatory Agents;
 - (A) Corticosteroids;
 - (B) Nonsteroidal Anti-inflammatory Agents;
 - (C) Anti-inflammatory Agents, Miscellaneous.
 - (d) Local Anesthetics;
 - (e) Mydriatics;
 - (f) Mouthwashes and Gargles;
 - (g) Vasoconstrictors;
 - (h) Antiglaucoma Agents;
 - (A) α -Adrenergic Agonists;
 - (B) β -Adrenergic Agents;
 - (C) Carbonic Anhydrase Inhibitors;
 - (D) Miotics;

- (E) Prostaglandin Analogs;
- (i) EENT Drugs, Miscellaneous.
- (16) Gastrointestinal Drugs;
- (a) Antacids and Adsorbents;
- (b) Antidiarrhea Agents;
- (c) Antiflatulents;
- (d) Cathartics and Laxatives;
- (e) Cholelitholytic Agents;
- (f) Emetics;
- (g) Antiemetics;
- (A) Antihistamines;
- (B) 5-HT₃ Receptor Antagonists;
- (C) Antiemetics, Miscellaneous.
- (h) Antiulcer Agents and Acid Suppressants;
- (A) Histamine H₂-Antagonists;
- (B) Prostaglandins;
- (C) Protectants;
- (D) Proton-pump Inhibitors;
- (i) Prokinetic Agents;
- (j) Anti-inflammatory Agents;
- (k) GI Drugs, Miscellaneous.
- (17) Gold Compounds.
- (18) Heavy Metal Antagonists.

NOTE: IV administration requires education and training compliance with 850-060-0212.

- (19) Endocrine Metabolic Agents;
- (a) Adrenals;
- (b) Androgens;
- (c) Contraceptives;
- (d) Corticosteroids;
- (e) Estrogens and Antiestrogens;
- (A) Estrogens;
- (B) Estrogen Agonists-Antagonists.
- (f) Gonadotropins;
- (g) Antidiabetic Agents;
- (A) α -Glucosidase Inhibitors;
- (B) Amylinomimetics;
- (C) Biguanides;
- (D) Dipeptidyl Peptidase (DDP-4) Inhibitors;
- (E) Incretin Mimetics;
- (F) Insulins;
- (G) Meglitinides;
- (H) Sulfonylureas;
- (I) Thiazolidinediones;
- (J) Miscellaneous.
- (h) Antihypoglycemic Agents: Glycogenolytic Agents;
- (i) Parathyroid;
- (j) Pituitary;
- (k) Somatotropin Agonists and Antagonists;
- (A) Somatotropin Agonists;
- (B) Somatotropin Antagonists;
- (l) Progestins;
- (m) Prostaglandin;

- (n) Thyroid and Antithyroid Agents;
- (A) Thyroid Agents;
- (B) Antithyroid Agents.
- (20) Local Anesthetics.
- (21) Oxytocics, not to be used as an abortifacient.
- (22) Serums, Toxoids, and Vaccines;
- (a) Serums;
- (b) Toxoids;
- (c) Vaccines.
- (23) Skin and Mucous Membrane Agents;
- (a) Anti-infectives;
- (A) Antibacterials;
- (B) Antivirals;
- (C) Antifungals;
- (i) Allylamines;
- (ii) Azoles;
- (iii) Benzylamines;
- (iv) Hydroxypyridones;
- (v) Polyenes;
- (vi) Thiocarbamates;
- (vii) Antifungals, Miscellaneous.
- (D) Scabicides and Pediculicides;
- (E) Local Anti-infectives, Miscellaneous.
- (b) Anti-inflammatory Agents;
- (c) Antipruritics and Local Anesthetics;
- (d) Astringents;
- (e) Cell Stimulants and Proliferants;
- (f) Detergents;
- (g) Emollients, Demulcents, and Protectants;
- (h) Keratolytic Agents;
- (i) Keratoplastic Agents;
- (j) Depigmenting and Pigmenting Agents;
- (A) Depigmenting Agents;
- (B) Pigmenting Agents;
- (k) Sunscreen Agents;
- (l) Skin and Mucous Membrane Agents, Miscellaneous.
- (24) Smooth Muscle Relaxants;
- (a) Gastrointestinal Smooth Muscle Relaxants;
- (b) Genitourinary Smooth Muscle Relaxants;
- (c) Respiratory Smooth Muscle Relaxants.
- (25) Vitamins, Minerals and Nutrients.
- (26) Miscellaneous Therapeutic Agents;
- (a) Alcohol Deterrents limited to the following:
- (A) Acamprosate;
- (B) Disulfiram;
- (C) Naltrexone.
- (b) 5-a Reductase Inhibitors;
- (c) Antidotes;
- (d) Antigout Agents;
- (e) Biologic Response Modifiers;
- (f) Bone Resorption Inhibitors;
- (g) Cariostatic Agents;

- (h) Complement Inhibitors;
- (i) Disease-Modifying Antirheumatic Agents;
- (j) Gonadotropin-releasing Hormone Antagonists;
- (k) Hyaluronic Acid;
- (l) Immunosuppressive Agents;
- (m) Oxygen;
- (n) Other Miscellaneous Therapeutic Agents limited to the following:
 - (A) Alfuzosin Hydrochloride;
 - (B) Drotrecogin Alfa (Activated);
 - (C) Lanreotide Acetate;
 - (D) Rilonacept;
 - (E) Sapropterin Dihydrochloride;
 - (F) Tamsulosin Hydrochloride.

Stat. Auth.: ORS 685.125

Stats. Implemented: ORS 685.145

Hist.: BNE 1-2002, f. & cert. ef. 2-19-02; BNE 4-2002, f. & cert. ef. 8-8-02; BNE 3-2003, f. & cert. ef. 6-9-03; BNE 5-2003, f. & cert. ef. 12-5-03; BNE 5-2004, f. & cert. ef. 6-10-04; Renumbered from 850-010-0226, BNE 8-2005, f. & cert. ef. 10-27-05; BNE 9-2005, f. & cert. ef. 12-12-05; BNE 4-2006, f. & cert. ef. 12-11-06; BNE 3-2007, f. & cert. ef. 6-12-07; BNE 1-2008, f. & cert. ef. 2-19-08; BNE 2-2008, f. & cert. ef. 3-21-08; BNE 6-2008, f. & cert. ef. 6-11-08; BNE 7-2008, f. & cert. ef. 12-8-08; BNE 2-2009, f. & cert. ef. 6-17-09; BNE 7-2009, f. 12-14-09, cert. ef. 1-1-10; OBNM 5-2010, f. & cert. ef. 6-30-10; OBNM 7-2010, f. & cert. ef. 12-13-10; OBNM 2-2011, f. & cert. ef. 4-12-11; OBNM 4-2011, f. & cert. ef. 6-15-11; OBNM 3-2012, f. & cert. ef. 6-15-12; OBNM 1-2014, f. & cert. ef. 4-9-14; OBNM 3-2014, f. & cert. ef. 7-10-14; OBNM 5-2015, f. & cert. ef. 8-28-15